Strides’ Stelis Completes $195m Funding Rounds
Biopharmaceuticals Business Cites ‘Significant Interest From Marquee Investors’
Executive Summary
Strides says its Stelis biopharmaceuticals unit is now well-placed to pursue key growth initiatives after completing Series B and Series C funding rounds worth $195m that value the business at around $350m overall.